The Blood Transfusion Diagnostics Market: Overview
The Blood Transfusion Diagnostics Market is valued at around USD 4.73 billion in 2022 and is expected to reach USD 8.7 billion by 2030, registering a CAGR of 7% over the forecast period. Transfusion of blood is the process of giving bloodeither as a whole or as a component of bloodby intravenous means to another person. Red blood cells, white blood cells, platelets, plasma, and clotting factors are all parts of blood. Before being given from one person to another, blood must be examined because it could transmit an infection or blood-borne diseases like post-transfusion purpura, anaphylaxis, delayed hemolytic reactions, and febrile non-hemolytic reactions.
The Blood Transfusion Diagnostics Market - Growth Factor
The market for blood products and total blood transfusions has grown as blood-related diseases like haemophilia, cancer, thrombocytopenia, and others are becoming more common, as is chronic kidney disease (CKD). Additionally, it is anticipated that the demand for blood transfusion diagnostics will grow significantly due to the rising number of anaemic patients who require red blood cell transfusion for diagnosis. The demand for blood screening tests and other diagnostic tools is rising as a result of increased awareness about blood safety from viral infections thanks to numerous programmes in both industrialised and developing nations.
The Blood Transfusion Diagnostics Market Market Trends
Dialysis is a kidney failure treatment that purifies the blood to get rid of extra fluid, toxins, and waste.
The body may have trouble cleansing the blood and maintaining the chemical balance of the body when the kidneys fail.
This is anticipated to increase demand for these blood transfusion diagnostics during the anticipated time frame.
The primary cause of death worldwide, according to the World Health Organization, is chronic cardiovascular disease. In addition, cardiovascular disease claimed the lives of about 18 million people.
The Blood Transfusion Diagnostics Market Segmentation
The Blood Transfusion Diagnostics Market fragrance concentrates market has been sub-classified into product type, application, end-user.
On the basis of products, the Blood Transfusion Diagnostics Market is bifurcated into:
Instruments
Reagents and kits
Others
On the basis of applications, the market is segmented into:
Blood group typing
Blood screening
Others
On the basis of end-user, the market segmented into:
Hospital based laboratories
Blood banks
Others
The Blood Transfusion Diagnostics Market Regional Analysis
North America dominated the global Blood Transfusion Diagnostics Market, is expected to continue to lead the world in blood transfusion diagnostics. Important growth factors include a high percentage of voluntary blood donors and the incorporation of blood transfusion policies for safety and communicable disease testing. Major players in the European blood transfusion diagnostics market include Germany and the UK. The development of the medical industry in these countries is responsible for the rise in surgical procedures and transplantation techniques.
The Blood Transfusion Diagnostics Market Key Market players
Global key players of Blood Transfusion Diagnostics Market include Grifols S.A., Bio-Rad Laboratories, Inc., Immucor, Inc., CSL Ltd., Abbott Laboratories, F. Hoffmann-La Roche Ltd, QUOTIENT, Merck KGaA, and DiaSorin S.p.A., and others.
Report scope
Global Blood Transfusion Diagnostics Market: Historical Years- 2018-2021
Global Blood Transfusion Diagnostics Marketp: Forecast Years- 2022-2030
Global Blood Transfusion Diagnostics Market 2022- USD 4.73 billion
Global Blood Transfusion Diagnostics Market 2030- USD 8.7 billion
Global Blood Transfusion Diagnostics Market CAGR- 7%
